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Fibulin-1 is associated with 
cardiovascular risk in non-obese,  
non-diabetic individuals
AbstrAct
Background. Fibulin-1 (FBLN1) is an extracellular matrix protein that appears in blood vessels. Recent 
studies have confirmed its role in atherogenesis, vascular complications and cardiovascular disease in 
chronic diseases such as diabetes mellitus. The aim of this study was to evaluate the association between 
serum fibulin-1 and biochemical indicators of cardiovascular risk: lipid profile, apolipoproteins B, AI, vitamin 
25(OH)D and high sensitivity troponin T (hs-cTnT) in non-diabetic subjects.
Materials and methods. The study consisted of 120 normoglycaemic, non-smoking, non-obese Caucasian 
subjects aged 25–40 (66 women and 54 men). Serum FBLN1 and plasma fasting glucose, lipid profile, 
C-reactive protein, insulin, glycated haemoglobin, apolipoproteins B100 and AI, total 25(OH)D, and 
hs-cTnT measurements were performed. Anthropometric parameters, HOMA-IR and atherogenic index 
(apoB:apoAI) were calculated. Carotid intima-media thickness (IMT) was measured using an ultrasound 
method. Subjects were divided by FBLN1 tertiles.
Results. FBLN1 was significantly higher in women than in men (1.06 vs. 0.96; p < 0.05). FBLN1 positively correlated, 
when adjusted for age, BMI and blood pressure, with lipid profile, atherogenic index, apolipoprotein B (R = 0.28; 
p < 0.016), and hs-cTnT (R=0.39; p < 0.003) and negatively with 25(OH)D. ApoB and hscTnT were significantly as-
sociated with fibulin-1 concentration and, together with 25(OH)D, explained 19% of its variation. FBLN1 ≥1.0 ng/mL 
predicted atherogenic risk with OR = 3.11 and 4.26 for having elevated apolipoprotein B and hs-TnT. 
Conclusions. Fibulin-1 might be a promissing risk factor for cardiovascular risk in young, non-obese, 
non-diabetic individuals, but this requires further investigation.
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Introduction
The fibulins are a family of seven proteins associated 
with elastic extracellular matrix fibres and basement mem-
branes. The characteristic feature in the structure of fibulins 
is a series of epidermal growth factor EGF-like modules, 
followed by specific fibulin-type module at the C-terminus 
of the peptide chain, which determines their properties [1]. 
Fibulin-1 (FBLN1) occurs in four variants (Fig. 1). 
This protein binds to tropoelastin and is associated 
with extracellular matrix fibres that contain elastin and 
fibrillins 1 and 2. FBLN1 is also related to elastin in 
the core of mature fibres in the skin and blood ves-
sels. FBLN1 is highly expressed during the development 
of the cardiovascular system (e.g. cardiac valvuloseptal 
and aortic-arch vessel formation) and is produced by 
cardiac mesenchymal cells and primordial vascular 
smooth muscle cells (VSMCs) [2]. Fibulin-1 may play 
a role in the development or progression of cardio-
vascular disease [3]. Recent studies have highlighted 
the role of FBLN1 in several human pathologies, such 
as myocardium dysfunction, cancer and retinopathy. 
However, there has only been one study reporting its 
relation to cardiovascular risk markers [3]. 
The aim of our study was to evaluate the association 
between serum fibulin-1 and biochemical indicators of 
cardiovascular risk in young non-obese, normoglycae-
mic subjects. 
subjects, materials and methods
The study included 120 normoglycaemic, non-
obese, non-smoking, Caucasian subjects with normal 
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blood pressure, aged 25–40 (66 women and 54 men) 
attending a routine medical examination who agreed 
to participate in the study. Written informed consent 
was obtained from each participant and the study was 
approved by the Bioethics Committee at Nicolaus Co-
pernicus University Collegium Medicum in Bydgoszcz, 
Poland. 
Fasting venous blood was drawn in the early morn-
ing into tubes containing sodium fluoride, EDTA and 
clotting activator in order to obtain plasma, whole blood 
and serum, respectively. Almost all laboratory tests 
were performed immediately after sample collection, 
otherwise the remaining serum was stored deep‐frozen 
(–80°C) in small aliquots for further assays. 
Laboratory tests were performed in the Depart-
ment of Laboratory Medicine, Collegium Medicum at 
Nicolaus Copernicus University. Fasting plasma glu-
cose, serum total cholesterol (TC), triglycerides (TG), 
HDL-cholesterol (HDL-C), C-reactive protein (CRP), 
apolipoproteins B100 and AI (apoB, apoAI) and gly-
cated haemoglobin (HbA1c) were measured using an 
Abbott ARCHITECT ci8200 analyser. Serum insulin, 
total 25-(OH)D and high sensitivity troponin T (hs-cT-
nT) were measured using a Roche Cobas e411 anal-
yser. The limit of detection for hs-cTnT was 3 pg/mL. 
Fibulin-1 (FBLN1) was assayed by ELISA (Wuhan 
EIAab Science) with a limit of detection of 0.1 ng/mL. 
LDL cholesterol (LDL-C), non-HDL cholesterol (non-
HDL-C), homeostatic model assessment (HOMA-IR), 
atherogenic index apoB:apoAI, body mass index 
(BMI), and waist-hip ratio (WHR) were calculated. The 
following values for routine laboratory parameters were 
considered normal: plasma glucose 3.33–5.5 mmol/L 
(60–99 mg/dL), insulin 2.6–24.9 μIU/mL, CRP < 1 mg/L, 
TC < 4.91 mmol/L (< 190 mg/dL), TG < 1.69 mmol/L 
(< 150 mg/dL), HDL-C > 1.03 mmol/L for men 
and > 1.16 mmol/L for women (> 40 and > 45 mg/dl, 
respectively), LDL-C < 2.97 mmol/L (< 115 mg/dL), 
non-HDL-C < 3.75 mmol/L (< 145 mg/dL), 25(OH)
D ≥ 30 ng/mL, hs-cTnT < 14 pg/mL (99th percentile 
for healthy individuals). An HbA1c concentration of 
29–42 mmol/mol Hb (4.8–6.0%) was accepted as 
a reference range for subjects without diabetes. The 
value of HbA1c ≤ 31.0 mmol/mol Hb, used in further 
calculations, was equal to estimated average glucose 
of ≤ 5.5 mmol/L.
Systolic and diastolic blood pressures (BP) were 
measured twice at 1–2 minutes intervals accord-
ing to standard procedures by trained personnel 
and < 130/85 mm Hg was accepted as normal [4]. 
Carotid intima-media thickness (IMT) as a marker of 
subclinical atherosclerosis was measured using an 
ultrasound method in the Department of Nephrology, 
Hypertension and Internal Diseases at Collegium Medi-
cum NCU. Values < 0.9 mm were considered normal.
statistics
Data is presented as mean ± standard deviation 
(normal distribution) or median and the 25th and 75th 
percentile (non‐Gaussian distribution). Statistical 
methods: t-Student’s test, U-Mann-Whitney test and 
multivariable regression analysis were performed using 
Statistica 9.0 for Windows (Stat Soft Inc.). P < 0.05 was 
considered statistically significant.
results
The clinical and biochemical characteristics of the study 
group are presented in Table 1. Significantly higher values of 
most parameters, except total cholesterol, LDL-C and CRP, 
were found in men. On the other hand, women had signifi-
cantly higher HDL-C, apoAI and 25(OH)D. Serum concen-
tration of fibulin-1 was in the range of 0.13 to 13.56 ng/mL 
and was higher in women. Of the study group, 16% were 
overweight (25–27.8 kg/m2), 32% had hypercholestero-
laemia, 34.5% had moderately increased CRP, and 45% 
had moderate 25(OH)D deficiency (10–20 ng/mL). Taking 
into consideration estimated average glucose of 
5.5 mmol/L equal to HbA1c of 31 mmol/mol Hb, in 58% of 
our normoglycaemic subjects the HbA1c concentration 
was over that cut-off. 
Figure 1. Fibulin-1 (FBLN1) and its variants (A–D) [2].
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Weak or moderate correlation of serum fibu-
lin-1 concentration and biochemical cardiovascular 
risk markers was observed which remained significant 
when adjusted for age, BMI and blood pressure (Tab. 2). 
The strongest correlation was found for FBLN1 and 
hs-cTnT (b = 0.39; p = 0.003), apoB (b = 0.28; 
p = 0.016) and non-HDL-C (b = 0.27; p = 0.001). 
Multivariable regression analysis was performed to 
assess the independent contributions of different 
variables to serum fibulin-1 concentration. The best 
model, with three independent variables: 25(OH)D, 
apoB and hscTnT, explained 19% of fibulin-1 con-
centration (R2 = 0.19; F = 8.31; p < 0.001) (Tab. 3). 
In this model, two independent variables, apoB and 
hs-cTnT, correlated weakly but significantly with 
fibulin-1. 
Table 1. Clinical and biochemical characteristics of the study group
Parameters All (n = 120) Women (n = 66) Men (n = 54)
Age [years] 30.8 ± 4.7 30.8 ± 4.9 31.03 ± 4.5
BMI [kg/m2] 22.7 (20–25) 21 (20–23) 24.5 (23–26.5)**
Systolic BP [mmHg] 117.8 ± 9.5 114 ± 9.2 123 ± 7.2**
Diastolic BP [mmHg] 80 ± 9.6 78.3 ± 8.6 82 ± 10.4*
Glucose [mmol/L] 4.98 ± 0.39 4.89 ± 0.36 5.11 ± 0.41**
HbA1c [mmol/mol] 32 (30–36) 32 (29–33) 34 (31–37)*
Insulin [μIU/mL] 7.62 ± 3.53 6.92 ± 2.7 8.53 ± 4.25*
HOMA-IR 1.56 (1.17–2.07) 1.43 (1.12–1.73) 1.69 (1.23–2.47)*
TC [mmol/L] 4.89 (3.21–5.33) 4.92 (4.39–5.25) 4.91 (4.31–5.37)
HDL-C [mmol/L] 1.42 (1.16–1.58) 1.53 (1.37–1.73) 1.19 (1.06–1.5)**
LDL-C [mmol/L] 2.94 (2.45–3.41) 2.76 (2.3–3.23) 3.02 (2.61–3.67)
TG [mmol/L] 0.92 (0.72–1.33) 0.85 (0.68–1.07) 1.16 (0.85–1.68)**
non-HDL-C [mmol/L] 3.44 (2.92–3.90) 3.36 (2.76–3.67) 3.72 (3.18–4.08)*
apoB [g/L] 0.76 (0.65–0.88) 0.73 (0.62–0.82) 0.82 (0.69–0.90)*
apoAI [g/L] 1.45 (1.31–1.64) 1.54 (1.41–1.74) 1.32 (1.19–1.53)**
apoB:apoAI 0.51 (0.41–0.61) 0.45 (0.38–0.53) 0.61 (0.52–0.74)**
CRP [mg/L] 0.6 (0.3–1.6) 0.5 (0.3–1.3) 0.7 (0.4–1.45)
25(OH)D [ng/mL] 18.4 (12.9–24.1) 20.1 (15.1–29.3) 15.3 (10.7–22.1)*
hs-cTnT [pg/mL] 4.72 (3.54–6.18) 4.67 (3.18–6.13) 5.07 (4.15–7.49)
IMT [mm] 0.55 (0.5–0.6) 0.5 (0.5–0.6) 0.6 (0.5–0.65)*
FBLN1 [ng/mL] 1.05 (0.88–1.22) 1.06 (0.96–1.22) 0.96 (0.71–1.17)*
Statistically significant differences between women vs. men: *p < 0.05; **p < 0.001
Table 2. Correlation of serum FBLN1 and selected cardiovascular risk markers (log-transformed variables)
Parameter
FBLN1
Unadjusted
Adjusted for age, BMI
and blood pressure
R p b p
25(OH)D –0.35 0.003 –0.23 0.015
TC 0.35 < 0.001 0.26 0.01
LDL-C 0.33 < 0.001 0.25 0.02
non-HDL-C 0.36 < 0.001 0.27 0.001
apoB 0.34 < 0.001 0.28 0.016
apoB:apoAI 0.22 0.014 0.19 0.02
hs-cTnT 0.42 < 0.001 0.39 0.003
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Afterwards, the distribution of selected cardiovascu-
lar risk factors was analysed according to fibulin-1 con-
centration in tertiles. Parameters such as apoB ≥ 0.9 g/L 
(≥ 90 mg/dL), non-HDL-C ≥ 3.75 mmol/L (≥ 145 mg/dL), 
25(OH)D >10–20 ng/mL and HbA1c > 31 mmol/mol Hb 
were used to define the risk. The prevalence of subjects 
with elevated apoB and non-HDL-C (Fig. 2) was 2.3-fold 
(12% vs. 28%) and 1.7-fold (24% vs. 40%) higher in the 
third tertile of fibulin-1 concentration, compared to the 
first one. The percentage of individuals with moderate 
25(OH)D deficiency increased from 32% in the first 
tertile of fibulin-1 concentration to 53% in the third tertile, 
whereas no differences were observed among subjects 
with HbA1c concentration over 31 mmol/mol (Fig. 3). 
Fibulin-1 concentration ≥ 1.0 ng/mL predicted athero-
genic risk with OR 3.1 (95% CI: 1.1–9.0; p = 0.03), 2.5 (95% 
CI: 1.1–57; p = 0.025) and 4.3 (95% CI: 1.9–9.7; p < 0.001) 
for having elevated apoB, non-HDL-C and hs-cTnT. 
Disscusion
Fibulin-1 seems to play an important role not only in 
the coagulation process, but also in atherogenesis and 
is found in atherosclerotic lesions [5]. Two recent stud-
ies have highlighted the significance of FBLN1 in car-
diovascular disease and vascular complications during 
chronic kidney disease and diabetes [3, 6]. The results 
presented in this study, performed in young and ap-
parently healthy normoglycaemic non-obese subjects, 
showed a significant association of serum FBLN1 with 
atherogenic risk markers. Moreover, FBLN1 was relat-
ed to high sensitivity cardiac troponin T which might 
reflect silent ischaemic disorders characterised by cTnT 
leakage and potential future coronary risk. Obtained 
results also indicated a negative association between 
serum FBLN1 and 25-hydroxyvitamin D concentration. 
Vitamin 25(OH)D insufficiency has long been known to 
be related to a higher risk of cardiovascular diseases. 
Interestingly, in our study we have not found any 
association of fibulin-1 with HbA1c, whereas the asso-
ciation with glucose was weak and observed only in 
tertiles of FBLN1 (glucose in the 1st tertile of FBLN1 was 
4.8 vs. 5.2 mmol/L in the 3rd tertile; p < 0.015; results not 
shown). These findings, in part, contradict the results of 
others [3, 6]. The study by Cangemi et al. [6] showed 
a higher expression of FBLN1 and its concentration in 
plasma in diabetic individuals compared to controls. The 
protein was detected in arterial wall by immunochemistry 
Table 3. Multivariable regression analysis on serum fibulin-1
Model Independent variable Adjusted R2 F b p
FBLN1 +
0.19 8.31 < 0.001
25(OH)D –0.17 0.08
apoB 0.22 0.02
hs-cTnT 0.26 0.01
Table 4. Odds ratio for atherogenic profile in subjects 
with FBLN1 over 1.0 ng/mL 
FBLN1 ≥ 1.0 ng/mL
OR 95% CI p
apoB ≥ 0.9 g/L 3.1 1.1–9.0 0.03
non-HDL-C ≥ 3.75 mmol/L 2.5 1.1–5.7 0.025
hs-cTnT ≥ 4.75 pg/mL 4.3 1.9–9.7 < 0.001
Figure 2. Prevalence of subjects with elevated apoB and non-HDL-C across FBLN1 tertiles
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staining, and its highest levels were found in external 
elastic membranes in both diabetic and healthy individu-
als. In T2DM subjects, FBLN1 was correlated with blood 
pressure but not carotid IMT. Moreover, the relationship 
between plasma FBLN1, glucose and HbA1c was found, 
but not with lipid profile. Fibulin-1 has been associated 
with overall and cardiovascular mortality in T2DM patients 
in a 15-year follow-up. A correlation between FBLN1 and 
NT-pro-BNP has also been confirmed in clinically healthy 
African men in the SAfrEIC study after adjustments for 
age, BMI, blood pressure, heart rate and estimated 
creatinine clearance [7], although the authors did not 
investigate the association of fibulin-1 with other bio-
chemical parameters and measures of arterial stiffness. 
Scholze et al. showed significantly increased values 
of plasma FBLN-1 in patients with chronic kidney disease 
with and without diabetes compared to controls [3]. Fi-
bulin-1 was strongly positively correlated with HbA1c and 
fibrinogen, creatinine, urea, and eGFR and negatively with 
heart rate. In this study, the correlation of FBLN-1 with 
HbA1c and eGFR was performed only in 12 patients. In 
multivariable regression analysis, FBLN1 was associated 
with diabetes in CKD patients (b = 0.40; p = 0.005).
In our study, young non-obese normoglycaemic 
subjects with normal blood pressure were included; this 
may explain these discrepancies. Using multiple linear 
regression analysis, we have shown that apoB and 
hscTnT are significantly associated with fibulin-1 con-
centration and, together with 25(OH)D, explain 19% of 
its variation. Additionally, fibulin-1 was found to predict 
atherogenic risk reflected by elevated apoB, non-HDL-C 
and hs-cTnT. Even if the relationship between fibu-
lin-1 and IMT was not found, it seems that in nondiabetic 
individuals the impact of atherogenic risk markers on 
FBLN1 may be stronger than the effect of glycaemia. 
The lack of large population-based studies looking 
into the role of fibulin-1 as a potential biomarker of car-
diovascular risk in clinically healthy, non-diabetic indi-
viduals makes it impossible to confirm our findings. We 
hope that planned follow-up studies on a larger sample 
will provide valuable information for a better assessment 
of FBLN1 in relation to cardiovascular risk markers. 
conclusions
Fibulin-1 seems to be a promising indicator of 
atherogenic risk in apparently healthy, non-diabetic 
subjects, but this requires further investigation in po-
pulation-based studies.
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